ZL-1310 is under clinical development by Zai Lab and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase I drugs for Small-Cell Lung Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ZL-1310’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ZL-1310 overview

ZL-1310 is under development for the treatment of small cell lung cancer. The therapeutic candidate is an antibody-drug conjugate (ADC) which acts by targeting cells expressing delta-like protein 3 (DLL3). It is being developed based on Tumor Microenvironment Activable LINker (TAMLIN) technology platform. It is administered through intravenous route.

Zai Lab overview

Zai Lab biopharmaceutical company that carries out drug development, discovery and commercializing therapies. The company product pipeline includes ZEJULA (niraparib), qinlock (ripretinib) NUZYRA (omadacycline) and optune (tumor treating fields). It includes discovering, developing and commercializing products that address medical conditions. Zai Lab therapeutic areas includes oncology, autoimmune disorders, infectious diseases and neuroscience. The company market its products to the United States, Europe, Canada, Australia, Greater China and certain other countries and regions. Zai Lab is headquartered in Shanghai, China.

For a complete picture of ZL-1310’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.